Prevalence of infection by human T Cell lymphotropic viruses (HTLV-1/2) in adult population in Vitoria-ES

Imagem de Miniatura
Arquivos
art_ORLETTI_Prevalence_of_infection_by_human_T_Cell_lymphotropic_2021.PDF (694.35 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2021
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
ORLETTI, Maria P. S.
SARNAGLIA, Glenia Daros
MARTINS, Marina Lobato
ROSADAS, Carolina
TAYLOR, Graham
FERREIRA-FILHO, Joaquim B.
PEREIRA, Fausto E. L.
MIRANDA, Angelica Espinosa
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.25, n.5, article ID 101631, 7p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Brazil has a high number of HTLV-1/2 infections which are unequally distributed in the country. Most prevalence studies have focused on specific populations, such as blood donors and pregnant women. Some areas, for example the state of Bahia, have robust information about HTLV-1/2 infection, however there is no information available about this infection in the general population of Vitoria, Espirito Santo, Brazil. Objective: To determine the prevalence of HTLV-1/2 infection in adults from the municipality of Vitoria, ES. Methods: A cross sectional study was performed from September 2010 to December 2011, in individuals of both sexes, aged 18 or older living in Vit = oria-ES. Venous blood samples were collected and tested for anti-HTLV-1/2 antibodies by chemiluminescent immunoassay (CMIA). Individuals with CMIA reactive results were submitted to a new blood collection for retesting by CMIA, followed by PCR to confirm infection and discriminate the viral type. Results: From 1502 tested samples, eight were reactive in CMIA and all were confirmed by PCR. Therefore, the prevalence of HTLV-1/2 was 0.53% (8/1502, 95% CI: 0.2-1.0%). The infection rate was 0.7% in men (5/711, 95% CI: 0.17-1.51%), and 0.38% in women (3/791, 95% CI: 0 - 0.81%). Conclusions: The prevalence of HTLV-1/2 infection was 0.53% (8/1502; 95% CI: 0.2 - 0.9%). Confirmatory test using real-time PCR (qPCR) identified seven individuals positive for HTLV-1 and one for HTLV-2. Considering the risk of infected individuals to develop high morbidity and mortality diseases, it would be important to implement public health policies aimed at stopping transmission of these viruses in this municipality. (C) 2021 Sociedade Brasileira de Infectologia.
Palavras-chave
HTLV-1, HTLV-2, Prevalence, General Population, Vitoria, Brazil
URI
https://observatorio.fm.usp.br/handle/OPI/44302
Referências
  1. Alves FA, 2018, BRAZ J INFECT DIS, V22, P123, DOI 10.1016/j.bjid.2018.03.002
  2. Andrade RG, 2010, REV SOC BRAS MED TRO, V43, P111, DOI 10.1590/S0037-86822010000200001
  3. [Anonymous], NEW WHO REPORT HUMAN
  4. Bandeira LM, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009066
  5. Bangham CRM, 2018, ANNU REV IMMUNOL, V36, P43, DOI 10.1146/annurev-immunol-042617-053222
  6. Carneiro-Proietti ABF, 2006, REV PANAM SALUD PUBL, V19, P44, DOI 10.1590/S1020-49892006000100007
  7. Castro LS, 2018, BRAZ J INFECT DIS, V22, P472, DOI 10.1016/j.bjid.2018.11.003
  8. Catalan-Soares Bernadette, 2005, Cad. Saúde Pública, V21, P926, DOI 10.1590/S0102-311X2005000300027
  9. Caterino-de-Araujo A, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0378-2019
  10. Caterino-de-Araujo A, 2015, AIDS RES HUM RETROV, V31, P543, DOI [10.1089/aid.2014.0287, 10.1089/AID.2014.0287]
  11. Lima Waleska Mayara Gomes de, 2013, Rev. Bras. Hematol. Hemoter., V35, P268, DOI 10.5581/1516-8484.20130061
  12. de Souza VG, 2012, REV SOC BRAS MED TRO, V45, P159, DOI 10.1590/S0037-86822012000200004
  13. DEARAUJO AC, 1994, EUR J EPIDEMIOL, V10, P165, DOI 10.1007/BF01730366
  14. Eusebio-Ponce E, 2019, REV ESP QUIM, V32, P485
  15. Galetto LR, 2014, AIDS RES HUM RETROV, V30, P907, DOI [10.1089/aid.2013.0210, 10.1089/AID.2013.0210]
  16. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  17. Gon Denise Utsch, 2020, B EPIDEMIOLOGICO, V51
  18. Gotuzzo E, 2007, REV PANAM SALUD PUBL, V22, P223, DOI 10.1590/S1020-49892007000900001
  19. Ishak R, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-0512-z
  20. Kozlowski AG, 2016, REV INST MED TROP SP, V58, DOI 10.1590/S1678-9946201658080
  21. Martin F, 2018, LANCET, V391, P1893, DOI 10.1016/S0140-6736(18)30974-7
  22. de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
  23. Ml M, 2017, J NEUROVIROL, V23
  24. Morimoto HK, 2005, AIDS RES HUM RETROV, V21, P256, DOI 10.1089/aid.2005.21.256
  25. Nunes D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171303
  26. Paiva A, 2017, J MED VIROL, V89, P1287, DOI 10.1002/jmv.24745
  27. Paiva A, 2015, REV INST MED TROP SP, V57, P1, DOI 10.1590/S0036-46652015000100001
  28. Paiva AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25939-y
  29. Pereira FM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0223087
  30. POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
  31. Ramassamy JL, 2020, BLOOD ADV, V4, P2044, DOI 10.1182/bloodadvances.2020001628
  32. Reboucas KAAF, 2019, HEMATOL TRANSF CELL, V41, P324, DOI 10.1016/j.htct.2019.03.007
  33. Rosadas C, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00999
  34. Talarmin A, 1999, J GEN VIROL, V80, P3083, DOI 10.1099/0022-1317-80-12-3083

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - LIM/56